

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAKAB1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	NOV 21	CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present
NEWS	3	NOV 26	MARPAT enhanced with FSORT command
NEWS	4	NOV 26	CHEMSAFE now available on STN Easy
NEWS	5	NOV 26	Two new SET commands increase convenience of STN searching
NEWS	6	DEC 01	ChemPort single article sales feature unavailable
NEWS	7	DEC 12	GBFULL now offers single source for full-text coverage of complete UK patent families
NEWS	8	DEC 17	Fifty-one pharmaceutical ingredients added to PS
NEWS	9	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS	10	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS	11	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS	12	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS	13	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS	14	FEB 10	COMPENDEX reloaded and enhanced
NEWS	15	FEB 11	WTEXTILES reloaded and enhanced
NEWS	16	FEB 19	New patent-examiner citations in 300,000 CA/CAPLUS patent records provide insights into related prior art
NEWS	17	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS	18	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS	19	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS	20	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS	21	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS	22	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS	23	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats
NEWS	24	MAR 11	EPFULL backfile enhanced with additional full-text applications and grants
NEWS	25	MAR 11	ESBIOBASE reloaded and enhanced
NEWS	26	MAR 20	CAS databases on STN enhanced with new super role

for nanomaterial substances
NEWS 27 MAR 23 CA/CAPLUS enhanced with more than 250,000 patent
equivalents from China
NEWS 28 MAR 30 IMSPATENTS reloaded and enhanced

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN customer
agreement. This agreement limits use to scientific research. Use
for software development or design, implementation of commercial
gateways, or use of CAS and STN data in the building of commercial
products is prohibited and may result in loss of user privileges
and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:33:08 ON 30 MAR 2009

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 14:33:16 ON 30 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 27 MAR 2009 HIGHEST RN 1128305-29-2
DICTIONARY FILE UPDATES: 27 MAR 2009 HIGHEST RN 1128305-29-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.


Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10572778.str



```

chain nodes :
10 11 12 13
ring nodes :
1 2 3 4 5 6 7 8 9 14
chain bonds :
9-10 10-11 11-12 11-13 11-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
5-7 7-8 9-10 10-11 11-12 11-13 11-14
exact bonds :
6-9 8-9
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:CLASS 14:Atom
Generic attributes :
10:
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic


```

L1 STRUCTURE UPLOADED

=> d L1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.96

1.18

FILE 'CAPLUS' ENTERED AT 14:34:11 ON 30 MAR 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Mar 2009 VOL 150 ISS 14

FILE LAST UPDATED: 29 Mar 2009 (20090329/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 11 SSS full

REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...

Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 14:34:15 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 118058 TO ITERATE

100.0% PROCESSED 118058 ITERATIONS 180 ANSWERS
SEARCH TIME: 00.00.04

L2 180 SEA SSS FUL L1

L3 7 L2

=> d ibib abs hitstr 1-
YOU HAVE REQUESTED DATA FROM 7 ANSWERS - CONTINUE? Y/(N):y

L3 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2009:140234 CAPLUS Full-text
DOCUMENT NUMBER: 150:199381
TITLE: A new combination of (a) an
 α -4- β -2-neuronal nicotinic agonist and (b)
a glycogen synthase kinase 3 (GSK3) inhibitor
INVENTOR(S): Basun, Hans; Cox, Graham; Nordgren, Ingrid; Bencherif,
Merouane
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Targacept, Inc.
SOURCE: PCT Int. Appl., 48pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2009017455	A1	20090205	WO 2008-SE50898	20080729
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: US 2007-952690P P 20070730

AB The present invention related to a combination of (a) a α 4 β 2-neuronal nicotinic agonist and (b) a GSK3 inhibitor. The invention further relates to pharmaceutical compns. comprising said combination and to methods of treating CNS disorders in mammals by administrating said combination. The invention further relates to a kit comprising the combination and use of said kits in treatment of CNS disorders such as dementia and/or Alzheimer's Disease.


IT 698345-96-9 733737-00-3

RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(combination of an α -4- β -2-neuronal nicotinic agonist and a glycogen synthase kinase 3 (GSK3) inhibitor for dementia therapy)


RN 698345-96-9 CAPLUS

CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]- (CA INDEX NAME)



RN 733737-00-3 CAPLUS

CN 1H-Indole-6-carbonitrile, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2009:139703 CAPLUS Full-text

DOCUMENT NUMBER: 150:222265

TITLE: New therapeutic combination of an antipsychotic and a glycogen synthase kinase 3 (GSK3) inhibitor 958

INVENTOR(S): Basun, Hans; Cox, Graham; Nordgren, Ingrid

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.

SOURCE: PCT Int. Appl., 54pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2009017453	A1	20090205	WO 2008-SE50896	20080729
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,			

TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2007-952641P P 20070730


AB The present invention relates to a combination of (a) an antipsychotic and (b) a GSK3 inhibitor. The invention further relates to pharmaceutical compns. comprising said combination and to methods of treating psychiatric disorders; particularly, cognitive impairment disorders in psychotic disorders in mammals by administrating said combination. The invention further relates to a kit comprising the combination and use of said kit in treatment of psychiatric disorders; particularly, cognitive impairment disorders in psychotic disorders.

IT 698345-96-9, 2-Hydroxy-3-[5-(4-methylpiperazin-1-yl)sulfonylpyridin-2-yl]-1H-indole-5-carbonitrile 733737-00-3
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(therapeutic combination of an antipsychotic and a glycogen synthase kinase 3 (GSK3) inhibitor 958)


RN 698345-96-9 CAPLUS

CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]- (CA INDEX NAME)



RN 733737-00-3 CAPLUS

CN 1H-Indole-6-carbonitrile, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]- (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2009:138859 CAPLUS Full-text

DOCUMENT NUMBER: 150:222260

TITLE: New therapeutic combination of a glycogen synthase kinase-3 (GSK3) inhibitor and an α 7-nicotinic agonist

INVENTOR(S): Basun, Hans; Cox, Graham; Nordgren, Ingrid

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.

SOURCE: PCT Int. Appl., 59pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009017454	A1	20090205	WO 2008-SE50897	20080729
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: US 2007-952651P P 20070730

AB The present invention related to a combination of (a) a GSK3 inhibitor and (b) an $\alpha 7$ - nicotinic agonist. The invention further relates to pharmaceutical compns. comprising said combination and to methods of treating CNS disorders in mammals by administrating said combination. The invention further relates to a kit comprising the combination and use of said kits in treatment of CNS disorders such as dementia and/or Alzheimer's Disease.


IT 698345-96-9 733737-00-3

RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(combination of a glycogen synthase kinase-3 (GSK3) inhibitor and an $\alpha 7$ -nicotinic agonist for dementia therapy)


RN 698345-96-9 CAPLUS

CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]- (CA INDEX NAME)



RN 733737-00-3 CAPLUS


CN 1H-Indole-6-carbonitrile, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]- (CA INDEX NAME)




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:283287 CAPLUS Full-text
DOCUMENT NUMBER: 142:336240
TITLE: Preparation of heterocyclic-substituted indoles as inhibitors of GSK3 β
INVENTOR(S): Berg, Stefan; Hellberg, Sven
PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.
SOURCE: PCT Int. Appl., 120 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2005027823	A2	20050331	WO 2004-SE1363	20040921
WO 2005027823	A3	20050602		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004273771	A1	20050331	AU 2004-273771	20040921
AU 2004273771	B2	20081106		
CA 2538381	A1	20050331	CA 2004-2538381	20040921
EP 1667990	A2	20060614	EP 2004-775465	20040921
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR			
BR 2004014632	A	20061107	BR 2004-14632	20040921
CN 1886397	A	20061227	CN 2004-80034700	20040921
JP 2007506734	T	20070322	JP 2006-527944	20040921
IN 2006DN01198	A	20070803	IN 2006-DN1198	20060307
US 20080275041	A1	20081106	US 2006-572778	20060321
MX 2006003195	A	20060623	MX 2006-3195	20060322
PRIORITY APPLN. INFO.:			SE 2003-2546	A 20030924
			AU 2003-216026	A3 20030328
			WO 2004-SE1363	W 20040921
OTHER SOURCE(S):	CASREACT 142:336240; MARPAT 142:336240			
GI				



- AB Title compds. I [P = 5-6-membered heteroarom. ring; R1 = H; R2 = alkyl, CN, halo, etc.; R3 = alkyl, CN, NO2, carboxy, etc.; m, n = 0-4] and derivs. are prepared For instance, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)carbonyl]pyridin-2-yl]-1H-indole-6-carbonitrile is prepared by the reaction of 2-oxoindoline-6-carbonitrile and 1-[(6-chloro-1-oxidopyridin-3-yl)carbonyl]-4-methylpiperazine (preparation given). Ki of selected compds. of the invention was 20 μ M for GSK3 β . I are useful for the treatment of, e.g., Alzheimer's Disease.
- IT 698345-96-9P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carbonitrile
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of heterocyclic-substituted indoles as inhibitors of GSK3 β)
- RN 698345-96-9 CAPLUS
- CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]- (CA INDEX NAME)



- IT 848472-62-8P, 2-Hydroxy-3-[5-(piperazine-1-sulfonyl)pyridin-2-yl]-1H-indole-6-carbonitrile hydrochloride 848472-64-0P,
 3-[5-[[4-[2-(Dipropylamino)ethyl]piperazin-1-yl)sulfonyl]pyridin-2-yl]-2-hydroxy-1H-indole-6-carbonitrile hydrochloride 848472-66-2P,
 3-[5-[[4-[2-(Dipropylamino)ethyl]piperazin-1-yl)sulfonyl]pyridin-2-yl]-2-hydroxy-1H-indole-6-carbonitrile 848472-68-4P,
 2-Hydroxy-3-[5-[[4-[2-(morpholin-4-yl)ethyl]piperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-6-carbonitrile hydrochloride 848472-70-8P,
 2-Hydroxy-3-[5-[[4-[2-(morpholin-4-yl)ethyl]piperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-6-carbonitrile 848472-72-0P,
 2-Hydroxy-3-[5-[[4-[2-(pyrrolidin-1-yl)ethyl]piperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-6-carbonitrile hydrochloride 848472-74-2P,
 2-Hydroxy-3-[5-[[4-[2-(pyrrolidin-1-yl)ethyl]piperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-6-carbonitrile 848472-76-4P,
 2-Hydroxy-3-[5-[[4-(2-methoxyethyl)piperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-6-carbonitrile hydrochloride 848472-78-6P,
 2-Hydroxy-3-[5-[[4-(2-methoxyethyl)piperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-6-carbonitrile 848472-80-0P,
 2-Hydroxy-N-(3-methoxypropyl)-3-[5-[(4-methylpiperazin-1-


yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride
848472-82-2P, 2-Hydroxy-N-(3-methoxypropyl)-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide
848473-33-6P, 2-Hydroxy-N-(2-methoxyphenyl)-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide
hydrochloride 848473-35-8P,
2-Hydroxy-N-(2-methoxyphenyl)-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide 848473-39-2P,
2-Hydroxy-N-(4-methoxyphenyl)-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride
848473-41-6P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-[(pyridin-3-yl)methyl]-1H-indole-5-carboxamide
hydrochloride 848473-43-8P,
2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-[(pyridin-4-yl)methyl]-1H-indole-5-carboxamide hydrochloride 848473-45-0P,
2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-[(pyridin-2-yl)methyl]-1H-indole-5-carboxamide hydrochloride 848473-58-5P,
2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-sulfonamide hydrochloride 848473-61-0P,
2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-63-2P,
2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-6-carboxamide hydrochloride 848473-64-3P,
3-[5-[[4-[2-(Dimethylamino)ethyl]piperazin-1-yl)sulfonyl]pyridin-2-yl]-2-hydroxy-1H-indole-6-carbonitrile hydrochloride 848473-68-7P,
2-Hydroxy-N-[2-(1H-imidazol-4-yl)ethyl]-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride
848473-69-8P, 2-Hydroxy-N-[2-(1H-imidazol-4-yl)ethyl]-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide
848473-70-1P, N-Benzyl-2-hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride
848473-71-2P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-propyl-1H-indole-5-carboxamide hydrochloride
848473-72-3P, 2-Hydroxy-N-(2-methoxyethyl)-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide
hydrochloride 848473-73-4P,
N-[2-(Dimethylamino)ethyl]-2-hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride
848473-77-8P, 6-Bromo-2-hydroxy-N-methyl-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride
848473-78-9P, 6-Bromo-2-hydroxy-N-isopropyl-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide
hydrochloride 848473-79-0P,
6-Bromo-2-hydroxy-N-(2-methoxyethyl)-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride
848473-80-3P, 6-Bromo-2-hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-[(tetrahydrofuran-2-yl)methyl]-1H-indole-5-carboxamide
hydrochloride 848473-81-4P,
6-Bromo-2-hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-[2-(pyrrolidin-1-yl)ethyl]-1H-indole-5-carboxamide hydrochloride
848473-82-5P, N-[3-(Dimethylamino)propyl]-2-hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide
hydrochloride 848473-83-6P,
2-Hydroxy-N-(2-methoxyethyl)-3-[5-[(morpholin-4-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-84-7P,
2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-pyridin-3-yl-1H-indole-5-carboxamide hydrochloride 848473-85-8P,
2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-pyridin-3-yl-1H-indole-5-carboxamide 848473-86-9P,
2-Hydroxy-N-(2-methoxybenzyl)-3-[5-[(4-methylpiperazin-1-

yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride
 848473-87-0P, 2-Hydroxy-N-(2-methoxybenzyl)-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide
 848473-88-1P, 2-Hydroxy-N-(3-methoxybenzyl)-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-89-2P,
 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-(tetrahydro-2H-pyran-4-yl)-1H-indole-5-carboxamide hydrochloride 848473-90-5P, 2-Hydroxy-N-(4-methoxybenzyl)-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-91-6P,
 2-Hydroxy-N-(4-methoxybenzyl)-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide 848474-01-1P,
 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxylic acid hydrochloride 848474-02-2P,
 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-[3-(2-oxopyrrolidin-1-yl)propyl]-1H-indole-5-carboxamide hydrochloride 848474-03-3P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-[(thiophene-2-yl)methyl]-1H-indole-5-carboxamide hydrochloride 848474-04-4P,
 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-[2-(2-oxoimidazolidin-1-yl)ethyl]-1H-indole-5-carboxamide hydrochloride 848474-05-5P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-[2-(thiophen-2-yl)ethyl]-1H-indole-5-carboxamide hydrochloride 848474-06-6P,
 N-[2-(Acetylamino)ethyl]-2-hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848474-07-7P, N-(2-Cyanoethyl)-2-hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848474-08-8P, N-[2-(Aminosulfonyl)ethyl]-2-hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848474-09-9P,
 N-(Cyanomethyl)-2-hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848474-10-2P,
 2-Hydroxy-3-[5-(4-methylpiperazinesulfonyl)pyridin-2-yl]-1H-indole-5-carboxylic acid N-[(carbamoyl)methyl]amide hydrochloride 848474-11-3P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-[2-(methylsulfonyl)ethyl]-1H-indole-5-carboxamide hydrochloride 848567-90-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic-substituted indoles as inhibitors of GSK3 β)


RN 848472-62-8 CAPLUS

CN 1H-Indole-6-carbonitrile, 2-hydroxy-3-[5-(1-piperazinylsulfonyl)-2-pyridinyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 848472-64-0 CAPLUS
 CN 1H-Indole-6-carbonitrile, 3-[5-[[4-[2-(dipropylamino)ethyl]-1-piperazinyl]sulfonyl]-2-pyridinyl]-2-hydroxy-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 848472-66-2 CAPLUS
 CN 1H-Indole-6-carbonitrile, 3-[5-[[4-[2-(dipropylamino)ethyl]-1-piperazinyl]sulfonyl]-2-pyridinyl]-2-hydroxy- (CA INDEX NAME)




RN 848472-68-4 CAPLUS
 CN 1H-Indole-6-carbonitrile, 2-hydroxy-3-[5-[[4-[2-(4-morpholinyl)ethyl]-1-piperazinyl]sulfonyl]-2-pyridinyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 848472-70-8 CAPLUS
 CN 1H-Indole-6-carbonitrile, 2-hydroxy-3-[5-[[4-[2-(4-morpholinyl)ethyl]-1-piperazinyl]sulfonyl]-2-pyridinyl]- (CA INDEX NAME)



RN 848472-72-0 CAPLUS


CN 1H-Indole-6-carbonitrile, 2-hydroxy-3-[5-[[4-[2-(1-pyrrolidinyl)ethyl]-1-piperazinyl]sulfonyl]-2-pyridinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 848472-74-2 CAPLUS

CN 1H-Indole-6-carbonitrile, 2-hydroxy-3-[5-[[4-[2-(1-pyrrolidinyl)ethyl]-1-piperazinyl]sulfonyl]-2-pyridinyl]- (CA INDEX NAME)



RN 848472-76-4 CAPLUS


CN 1H-Indole-6-carbonitrile, 2-hydroxy-3-[5-[[4-(2-methoxyethyl)-1-piperazinyl]sulfonyl]-2-pyridinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 848472-78-6 CAPLUS

CN 1H-Indole-6-carbonitrile, 2-hydroxy-3-[5-[[4-(2-methoxyethyl)-1-piperazinyl]sulfonyl]-2-pyridinyl]- (CA INDEX NAME)



RN 848472-80-0 CAPLUS


CN 1H-Indole-5-carboxamide, 2-hydroxy-N-(3-methoxypropyl)-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 848472-82-2 CAPLUS

CN 1H-Indole-5-carboxamide, 2-hydroxy-N-(3-methoxypropyl)-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]- (CA INDEX NAME)



RN 848473-33-6 CAPLUS


CN 1H-Indole-5-carboxamide, 2-hydroxy-N-(2-methoxyphenyl)-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 848473-35-8 CAPLUS

CN 1H-Indole-5-carboxamide, 2-hydroxy-N-(2-methoxyphenyl)-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]- (CA INDEX NAME)



RN 848473-39-2 CAPLUS


CN 1H-Indole-5-carboxamide, 2-hydroxy-N-(4-methoxyphenyl)-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-41-6 CAPLUS


CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-(3-pyridinylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 848473-43-8 CAPLUS


CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-(4-pyridinylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 848473-45-0 CAPLUS


CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-(2-pyridinylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 848473-58-5 CAPLUS


CN 1H-Indole-5-sulfonamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 848473-61-0 CAPLUS


CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-63-2 CAPLUS


CN 1H-Indole-6-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-64-3 CAPLUS


CN 1H-Indole-6-carbonitrile, 3-[5-[[4-[2-(dimethylamino)ethyl]-1-piperazinyl]sulfonyl]-2-pyridinyl]-2-hydroxy-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 848473-68-7 CAPLUS


CN 1H-Indole-5-carboxamide, 2-hydroxy-N-[2-(1H-imidazol-4-yl)ethyl]-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 848473-69-8 CAPLUS

CN 1H-Indole-5-carboxamide, 2-hydroxy-N-[2-(1H-imidazol-5-yl)ethyl]-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]- (CA INDEX NAME)



RN 848473-70-1 CAPLUS


CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-(phenylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 848473-71-2 CAPLUS

CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-propyl-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 848473-72-3 CAPLUS
 CN 1H-Indole-5-carboxamide, 2-hydroxy-N-(2-methoxyethyl)-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 848473-73-4 CAPLUS
 CN 1H-Indole-5-carboxamide, N-[2-(dimethylamino)ethyl]-2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 848473-77-8 CAPLUS
 CN 1H-Indole-5-carboxamide, 6-bromo-2-hydroxy-N-methyl-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-78-9 CAPLUS
 CN 1H-Indole-5-carboxamide, 6-bromo-2-hydroxy-N-(1-methylethyl)-3-[5-[(4-


methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-79-0 CAPLUS


CN 1H-Indole-5-carboxamide, 6-bromo-2-hydroxy-N-(2-methoxyethyl)-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-80-3 CAPLUS


CN 1H-Indole-5-carboxamide, 6-bromo-2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-[(tetrahydro-2-furanyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-81-4 CAPLUS


CN 1H-Indole-5-carboxamide, 6-bromo-2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-[2-(1-pyrrolidinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-82-5 CAPLUS


CN 1H-Indole-5-carboxamide, N-[3-(dimethylamino)propyl]-2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-83-6 CAPLUS


CN 1H-Indole-5-carboxamide, 2-hydroxy-N-(2-methoxyethyl)-3-[5-(4-morpholinylsulfonyl)-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-84-7 CAPLUS


CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-3-pyridinyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 848473-85-8 CAPLUS

CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-3-pyridinyl- (CA INDEX NAME)



RN 848473-86-9 CAPLUS


CN 1H-Indole-5-carboxamide, 2-hydroxy-N-[(2-methoxyphenyl)methyl]-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 848473-87-0 CAPLUS

CN 1H-Indole-5-carboxamide, 2-hydroxy-N-[(2-methoxyphenyl)methyl]-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]- (CA INDEX NAME)



RN 848473-88-1 CAPLUS


CN 1H-Indole-5-carboxamide, 2-hydroxy-N-[(3-methoxyphenyl)methyl]-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-89-2 CAPLUS


CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-(tetrahydro-2H-pyran-4-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 848473-90-5 CAPLUS


CN 1H-Indole-5-carboxamide, 2-hydroxy-N-[(4-methoxyphenyl)methyl]-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 848473-91-6 CAPLUS

CN 1H-Indole-5-carboxamide, 2-hydroxy-N-[(4-methoxyphenyl)methyl]-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]- (CA INDEX NAME)



RN 848474-01-1 CAPLUS


CN 1H-Indole-5-carboxylic acid, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 848474-02-2 CAPLUS


CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848474-03-3 CAPLUS


CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-(2-thienylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 848474-04-4 CAPLUS


CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-[2-(2-oxo-1-imidazolidinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848474-05-5 CAPLUS


CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-[2-(2-thienyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848474-06-6 CAPLUS


CN 1H-Indole-5-carboxamide, N-[2-(acetylamino)ethyl]-2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848474-07-7 CAPLUS


CN 1H-Indole-5-carboxamide, N-(2-cyanoethyl)-2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848474-08-8 CAPLUS


CN 1H-Indole-5-carboxamide, N-[2-(aminosulfonyl)ethyl]-2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848474-09-9 CAPLUS


CN 1H-Indole-5-carboxamide, N-(cyanomethyl)-2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848474-10-2 CAPLUS


CN 1H-Indole-5-carboxamide, N-(2-amino-2-oxoethyl)-2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 848474-11-3 CAPLUS


CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-[2-(methylsulfonyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848567-90-8 CAPLUS


CN 1H-Indole-5-carboxamide, N-(3-amino-3-oxopropyl)-2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]- (CA INDEX NAME)



IT 848473-37-0, Methyl 2-hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxylate
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of heterocyclic-substituted indoles as inhibitors of GSK3 β)

RN 848473-37-0 CAPLUS


CN 1H-Indole-5-carboxylic acid, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, methyl ester (CA INDEX NAME)



IT 848472-48-0P, Methyl 2-hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxylate hydrochloride
 848472-50-4P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxylic acid
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of heterocyclic-substituted indoles as inhibitors of GSK3 β)

RN 848472-48-0 CAPLUS


CN 1H-Indole-5-carboxylic acid, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 848472-50-4 CAPLUS

CN 1H-Indole-5-carboxylic acid, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]- (CA INDEX NAME)




REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2003:796689 CAPLUS Full-text
 DOCUMENT NUMBER: 139:323431
 TITLE: Preparation of heterocyclyl-substituted 2-oxindoles and 2,3-dihydro-1H-indol-2-ols as glycogen synthase kinase-3 inhibitors
 INVENTOR(S): Berg, Stefan; Hellberg, Sven; Nyloef, Martin; Xue, Yafeng
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
 SOURCE: PCT Int. Appl., 114 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003082853	A1	20031009	WO 2003-SE508	20030328
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2476343	A1	20031009	CA 2003-2476343	20030328
AU 2003216026	A1	20031013	AU 2003-216026	20030328
AU 2003216026	B2	20081211		
EP 1492785	A1	20050105	EP 2003-745498	20030328
EP 1492785	B1	20081203		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003008196	A	20050111	BR 2003-8196	20030328
CN 1642938	A	20050720	CN 2003-807389	20030328
JP 2005526814	T	20050908	JP 2003-580319	20030328
JP 3989444	B2	20071010		
CN 1923812	A	20070307	CN 2006-10153714	20030328
NZ 534664	A	20070629	NZ 2003-534664	20030328
EP 1961748	A2	20080827	EP 2008-157461	20030328
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR, AL, LT, LV, MK			
RU 2338742	C2	20081120	RU 2004-125146	20030328
AT 416171	T	20081215	AT 2003-745498	20030328

MX 2004009163	A	20041207	MX 2004-9163	20040921
ZA 2004007665	A	20050829	ZA 2004-7665	20040922
US 20050153987	A1	20050714	US 2004-509268	20040927
US 7399780	B2	20080715		
NO 2004004432	A	20041019	NO 2004-4432	20041019
JP 2007224051	A	20070906	JP 2007-155810	20070613
PRIORITY APPLN. INFO.:			SE 2002-979	A 20020328
			CN 2003-807389	A3 20030328
			EP 2003-745498	A3 20030328
			JP 2003-580319	A3 20030328
			WO 2003-SE508	W 20030328
OTHER SOURCE(S):			MARPAT 139:323431	
GI				



AB Title compds. I and II [wherein P = 5- or 6-membered heteroarom. ring; R₁ = H; R₂ and R₃ = independently halo, NO₂, alkenyl, alkynyl, alkylcycloalkyl, alkyl(hetero)aryl, CHO, COR₄, CO₂R₄, CH₂F, CHF₂, CF₃, OCH₂F, OCHF₂, OCF₃, OCO₂R₄, NR₄OR₅, NR₄CO₂R₅, SO₃R₄, XR₆; R₄ = H, alkyl, alkenyl, alkynyl, alkylcycloalkyl, alkyl(hetero)aryl, alkyl-NR₁₄R₁₅, or (un)substituted heterocyclyl; R₅ = H or (un)substituted alkyl, alkenyl, alkynyl, alkylcycloalkyl, alkyl(hetero)aryl, or alkyl-NR₁₄R₁₅; or NR₄R₅ = (un)substituted heterocyclyl; R₆ = (un)substituted Ph or heterocyclyl; R₇, R₉, and R₁₂ = independently H or alkyl; R₈, R₁₀, R₁₁, and R₁₃ = independently alkyl; R₁₄ and R₁₅ = independently H or alkyl(cycloalkyl); or NR₁₄R₁₅ = (un)substituted heterocyclyl; X = direct bond, O, COR₇R₈, SO₂NR₉R₁₀, or NR₁₂R₁₃; OCOR₄ (un)substituted alkyl or alkoxy; m = 0-4; n = 0-4; and their pharmaceutically acceptable salts thereof] were prepared as glycogen synthase kinase-3 (GSK3) inhibitors. For example, reduction of 5-cyanoindole with NaH in DMF, followed by coupling with 2-chloro-N-[2-(dimethylamino)ethyl]isonicotinamide in DMF provided the title indolol III (5%). In ATP competition assays, compds. of the invention inhibited recombinant human GSK3β with K_i values in the range of about 0.001 nM to about 10,000 nM (no specific values given). Thus, I, II, and their pharmaceutical formulations are useful for the treatment of a variety of neurodegenerative and dementia related diseases, including Alzheimer's disease (no data).


IT 612488-22-9P, 3-[3-Bromo-5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-5-nitro-1H-indol-2-ol

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(GSK3 inhibitor; preparation of (heterocycl)oxindoles and indolols as GSK3 inhibitors for treatment of neurodegenerative diseases, dementia, and related disorders)

RN 612488-22-9 CAPLUS

CN 1H-Indol-2-ol, 3-[3-bromo-5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-5-nitro- (CA INDEX NAME)




IT 612487-78-2P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carbonitrile hydrochloride
612488-00-3P, 3-[5-[(4-Methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indol-2-ol hydrochloride 612488-01-4P,
6-Chloro-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indol-2-ol hydrochloride 612488-14-9P,
3-[5-[(4-Benzylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-2-hydroxy-1H-indole-5-carbonitrile hydrochloride 612488-15-0P,
2-Hydroxy-3-[5-[[4-(3-methylbutyl)piperazin-1-yl]sulfonyl]pyridin-2-yl]-1H-indole-5-carbonitrile hydrochloride 612488-16-1P,
2-Hydroxy-3-[5-[(4-isopropylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carbonitrile hydrochloride 612488-17-2P,
3-[5-[(4-Ethylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-2-hydroxy-1H-indole-5-carbonitrile hydrochloride 612488-21-8P,
3-[3-Bromo-5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-5-nitro-1H-indol-2-ol hydrochloride 612488-24-1P,
2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-6-carbonitrile hydrochloride 612488-44-5P,
2-Hydroxy-3-[5-[(4-methyl-1,4-diazepan-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carbonitrile 612488-45-6P,
2-Hydroxy-3-[5-[(morpholin-4-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carbonitrile 612488-46-7P,
3-[5-[(4-Methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-5-(2-methylthiazol-4-yl)-1H-indol-2-ol hydrochloride 612488-48-9P,
3-[5-[(4-Methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-5-(thiazol-4-yl)-1H-indol-2-ol fumarate 612488-49-0P,
3-[5-[(4-Methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-5-(oxazol-5-yl)-1H-indol-2-ol 612488-57-0P,
2-Hydroxy-3-[5-[(4-methyl-1,4-diazepan-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carbonitrile fumarate

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(GSK3 inhibitor; preparation of (heterocycl)oxindoles and indolols as GSK3 inhibitors for treatment of neurodegenerative diseases, dementia, and related disorders)

RN 612487-78-2 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 612488-00-3 CAPLUS
CN 1H-Indol-2-ol, 3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 612488-01-4 CAPLUS
CN 1H-Indol-2-ol, 6-chloro-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 612488-14-9 CAPLUS
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[[4-(phenylmethyl)-1-piperazinyl]sulfonyl]-2-pyridinyl]-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 612488-15-0 CAPLUS
 CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[[4-(3-methylbutyl)-1-piperazinyl]sulfonyl]-2-pyridinyl]-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 612488-16-1 CAPLUS
 CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[[4-(1-methylethyl)-1-piperazinyl]sulfonyl]-2-pyridinyl]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl


RN 612488-17-2 CAPLUS
 CN 1H-Indole-5-carbonitrile, 3-[5-[(4-ethyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-2-hydroxy-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 612488-21-8 CAPLUS


CN 1H-Indol-2-ol, 3-[3-bromo-5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-5-nitro-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 612488-24-1 CAPLUS


CN 1H-Indole-6-carbonitrile, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl


RN 612488-44-5 CAPLUS

CN 1H-Indole-5-carbonitrile, 3-[5-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)sulfonyl]-2-pyridinyl]-2-hydroxy- (CA INDEX NAME)




RN 612488-45-6 CAPLUS

CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-(4-morpholinylsulfonyl)-2-pyridinyl]- (CA INDEX NAME)



RN 612488-46-7 CAPLUS

CN 1H-Indol-2-ol, 3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-5-(2-methyl-4-thiazolyl)-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl


RN 612488-48-9 CAPLUS

CN Piperazine, 1-[[6-[2-hydroxy-5-(4-thiazolyl)-1H-indol-3-yl]-3-pyridinyl]sulfonyl]-4-methyl-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 612488-47-8

CMF C21 H21 N5 O3 S2




CM 2

CRN 110-17-8


CMF C4 H4 O4

Double bond geometry as shown.



RN 612488-49-0 CAPLUS

CN 1H-Indol-2-ol, 3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-5-(5-oxazolyl)- (CA INDEX NAME)




RN 612488-57-0 CAPLUS

CN 1H-1,4-Diazepine, 1-[[6-(5-cyano-2-hydroxy-1H-indol-3-yl)-3-pyridinyl]sulfonyl]hexahydro-4-methyl-, (2E)-2-butenedioate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 612488-44-5

CMF C20 H21 N5 O3 S




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:312012 CAPLUS Full-text

DOCUMENT NUMBER: 136:340996

TITLE: Preparation of sulfamides as metalloprotease inhibitors

INVENTOR(S): Broka, Chris Allen; Campbell, Jeffrey Allen; Castelhana, Arlindo Lucas; Chen, Jian Jeffrey; Hendricks, Robert Than; Melnick, Michael Joseph; Walker, Keith Adrian Murray

PATENT ASSIGNEE(S): Syntex (U.S.A.) LLC, USA; Agouron Pharmaceuticals, Inc.

SOURCE: U.S., 47 pp., Cont.-in-part of U.S. 6,143,744. CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6376506	B1	20020423	US 1999-469677	19991222
CA 2278694	A1	19980730	CA 1998-2278694	19980114
CA 2278694	C	20060926		
AU 9866140	A	19980818	AU 1998-66140	19980114
AU 730127	B2	20010222		
EP 958287	A1	19991124	EP 1998-907943	19980114
EP 958287	B1	20020911		
EP 958287	B2	20080409		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK				
BR 9807508	A	20000321	BR 1998-7508	19980114
NZ 336625	A	20010427	NZ 1998-336625	19980114
HU 2000000941	A2	20010428	HU 2000-941	19980114
HU 2000000941	A3	20020628		
JP 2001523222	T	20011120	JP 1998-531537	19980114
JP 3563411	B2	20040908		
AT 223909	T	20020915	AT 1998-907943	19980114
ZA 9800376	A	19980723	ZA 1998-376	19980116
US 5998412	A	19991207	US 1998-9951	19980121
NO 9903587	A	19990922	NO 1999-3587	19990722
NO 313635	B1	20021104		
MX 9906822	A	20000131	MX 1999-6822	19990722
US 6130220	A	20001010	US 1999-369677	19990805
US 6143744	A	20001107	US 1999-369501	19990805
PRIORITY APPLN. INFO.:			US 1997-36714P	P 19970123
			US 1997-62209P	P 19971016
			US 1998-9951	A3 19980121
			US 1999-369501	A2 19990805
			WO 1998-EP180	W 19980114

OTHER SOURCE(S): MARPAT 136:340996


AB Sulfamides $\text{RCOCR}_1\text{R}_2\text{NR}_3\text{SO}_2\text{NR}_4\text{R}_5$ [$\text{R} = \text{OH}$, NHOH or N/O-alkyl or -aryl derivs.; R_1 , R_2 , $\text{R}_3 = \text{H}$, alkyl, alkenyl, haloalkyl, cycloalkyl, cycloalkylalkyl, (hetero)aryl, acylalkyl, etc.; $\text{R}_1\text{R}_2\text{C}$ may be a (hetero)carbocycle or R_3 together with R_1 or R_2 form a heterocycloamino group; R_4 , $\text{R}_5 = \text{H}$, alkyl, heteroalkyl, cycloalkyl, cycloalkylalkyl, aryl, (hetero)aralkyl or -aralkenyl ; $\text{R}_4\text{R}_5\text{N}$ may be a heterocycloamino group or R_4 or R_5 together with R_3 forms an alkylene group (with provisos)], as individual isomers or mixts. of isomers, or their pharmaceutically-acceptable salts or prodrugs were prepared as inhibitors of metalloproteases. Thus, 2-(R)-[(1,2,3,4-tetrahydro- β -carbolino-2-sulfonyl)amino]propionic acid (claimed compound) was prepared by treating D-alanine Me ester hydrochloride with chlorosulfonyl isocyanate/2-chloroethanol, reaction of the oxazolidone formed with 1,2,3,4-tetrahydro- β -carboline, and saponification Metalloprotease and $\text{TNF-}\alpha$ inhibitory test data are tabulated.

IT 1100982-59-9
 RL: PRPH (Prophetic)
 (Preparation of sulfamides as metalloprotease inhibitors)

RN 1100982-59-9 CAPLUS

CN 2-Piperazinecarboxamide, 4-(cyclopropylmethyl)-1-[[4-[5-fluoro-1-[[2-(trimethylsilyl)ethyl]sulfonyl]-1H-indol-3-yl]-1-piperidinyl]sulfonyl]-N-(phenylmethoxy)-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




IT 210916-51-1P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of sulfamides as metalloprotease inhibitors)

RN 210916-51-1 CAPLUS

CN 1,3-Piperazinedicarboxamide, N1,N1-dimethyl-N3-(phenylmethoxy)-4-[[4-(4,5,6,7-tetrafluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




IT 210915-38-1P 210915-40-5P 210915-57-4P
 210915-59-6P 210915-60-9P 210915-61-0P
 210915-69-8P 210915-71-2P 210915-72-3P
 210915-76-7P 210915-78-9P 210915-83-6P
 210915-86-9P 210915-87-0P 210915-88-1P
 210915-89-2P 210915-90-5P 210915-91-6P
 210915-92-7P 210915-93-8P 210915-94-9P
 210915-95-0P 210915-96-1P 210916-01-1P
 210916-05-5P 210916-08-8P 210916-09-9P
 210916-14-6P 210916-16-8P 210916-17-9P
 210916-46-4P 210916-47-5P 210916-48-6P
 210916-49-7P 210916-50-0P 210916-52-2P
 210916-53-3P 210916-54-4P 210916-55-5P
 210916-60-2P 210916-61-3P 210916-97-5P
 210917-01-4P 210917-04-7P 416846-37-2P
 416846-38-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of sulfamides as metalloprotease inhibitors)


RN 210915-38-1 CAPLUS

CN 2-Piperidinecarboxamide, 1-[[4-(5-fluoro-1H-indol-3-yl)-1-
 piperidinyl]sulfonyl]-N-hydroxy- (CA INDEX NAME)




RN 210915-40-5 CAPLUS

CN 2-Piperidinecarboxamide, 1-[[4-(6-chloro-1H-indol-3-yl)-1-
 piperidinyl]sulfonyl]-N-hydroxy- (CA INDEX NAME)




RN 210915-57-4 CAPLUS

CN 2-Piperidinecarboxamide, 1-[[4-(5-chloro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N-hydroxy- (CA INDEX NAME)




RN 210915-59-6 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-3-[(hydroxyamino)carbonyl]-, phenylmethyl ester (CA INDEX NAME)




RN 210915-60-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[4-(6-chloro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-3-[(hydroxyamino)carbonyl]-, phenylmethyl ester (CA INDEX NAME)




RN 210915-61-0 CAPLUS

CN 2-Piperazinecarboxamide, 4-acetyl-N-hydroxy-1-[[4-(6-methyl-1H-indol-3-yl)-1-piperidinyl]sulfonyl]- (CA INDEX NAME)



RN 210915-69-8 CAPLUS


CN 2-Piperidinecarboxamide, 1-[[4-(4-chloro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N-hydroxy- (CA INDEX NAME)



RN 210915-71-2 CAPLUS


CN 2-Piperidinecarboxamide, 1-[[4-(6-fluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 210915-72-3 CAPLUS

CN 2-Piperidinecarboxamide, N-hydroxy-1-[[4-(5-methoxy-1H-indol-3-yl)-1-piperidinyl]sulfonyl]- (CA INDEX NAME)



RN 210915-76-7 CAPLUS


CN 2-Piperidinecarboxamide, N-hydroxy-1-[[4-(5-hydroxy-1H-indol-3-yl)-1-piperidinyl]sulfonyl]- (CA INDEX NAME)



RN 210915-78-9 CAPLUS

CN 2-Piperidinecarboxamide, 1-[[4-(5-cyano-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N-hydroxy-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210915-83-6 CAPLUS


CN 2-Piperidinecarboxamide, N-hydroxy-1-[[4-(4,5,6,7-tetrafluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 210915-86-9 CAPLUS

CN 1,3-Piperazinedicarboxamide, N1-(1,1-dimethylethyl)-4-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N3-hydroxy- (CA INDEX NAME)




RN 210915-87-0 CAPLUS

CN 1-Piperazinecarboxylic acid, 3-[(hydroxyamino)carbonyl]-4-[[4-[4-[4,5,6,7-tetrafluoro-1-[[2-(trimethylsilyl)ethyl]sulfonyl]-1H-indol-3-yl]-1-piperidinyl]sulfonyl]-, phenylmethyl ester (CA INDEX NAME)




RN 210915-88-1 CAPLUS

CN 1-Piperazinecarboxylic acid, 3-[(hydroxyamino)carbonyl]-4-[[4-(4,5,6,7-tetrafluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-, phenylmethyl ester (CA INDEX NAME)




RN 210915-89-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-3-[(hydroxyamino)carbonyl]-, methyl ester (CA INDEX NAME)



RN 210915-90-5 CAPLUS


CN 2-Piperazinecarboxamide, 1-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N-hydroxy-4-[(tetrahydro-2H-pyran-4-yl)carbonyl]- (CA INDEX NAME)



RN 210915-91-6 CAPLUS

CN 2-Piperidinecarboxamide, 1-[[4-[5-(acetylamino)-1H-indol-3-yl]-1-piperidinyl]sulfonyl]-N-hydroxy-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210915-92-7 CAPLUS

CN 2-Piperazinecarboxamide, 4-[(2S)-2-amino-3-methyl-1-oxobutyl]-1-[[4-(6-fluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N-hydroxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 210915-93-8 CAPLUS

CN 1,3-Piperazinedicarboxamide, N3-hydroxy-N1,N1-dimethyl-4-[[4-(4,5,6,7-tetrafluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210915-94-9 CAPLUS


CN 2-Piperazinecarboxamide, 4-(cyclopropylmethyl)-1-[[4-(6-fluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 210915-95-0 CAPLUS

CN 2-Piperazinecarboxamide, 4-[(dimethylamino)sulfonyl]-1-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N-hydroxy- (CA INDEX NAME)



RN 210915-96-1 CAPLUS


CN 2-Piperazinecarboxamide, 4-[bis(dimethylamino)phosphinyl]-1-[[4-(6-fluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N-hydroxy- (CA INDEX NAME)



RN 210916-01-1 CAPLUS

CN 1,3-Piperazinedicarboxamide, 4-[[4-(5-cyano-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N1-(1,1-dimethylethyl)-N3-hydroxy-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210916-05-5 CAPLUS

CN 2-Piperazinecarboxamide, 1-[[4-(5-cyano-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N-hydroxy-4-(4-morpholinylcarbonyl)-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210916-08-8 CAPLUS

CN 2-Piperidinecarboxamide, 1-[[4-[5-cyano-1-(methylsulfonyl)-1H-indol-3-yl]-1-piperidinyl]sulfonyl]-N-hydroxy-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210916-09-9 CAPLUS

CN 3-Thiomorpholinecarboxamide, 4-[[4-(5-cyano-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N-hydroxy-2,2-dimethyl-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210916-14-6 CAPLUS


CN 2-Piperazinecarboxamide, 1-[[4-(5-cyano-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N-hydroxy-4-(2-pyrazinylcarbonyl)-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 210916-16-8 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[[4-[6-chloro-1-[[2-(trimethylsilyl)ethyl]sulfonyl]-1H-indol-3-yl]-1-piperidinyl]sulfonyl]-3-[(hydroxyamino)carbonyl]-, phenylmethyl ester (CA INDEX NAME)



RN 210916-17-9 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[[4-[6-fluoro-1-[[2-(trimethylsilyl)ethyl]sulfonyl]-1H-indol-3-yl]-1-piperidinyl]sulfonyl]-3-[(hydroxyamino)carbonyl]-, phenylmethyl ester (CA INDEX NAME)

[(hydroxyamino)carbonyl]-, phenylmethyl ester (CA INDEX NAME)



RN 210916-46-4 CAPLUS


CN 2-Piperazinecarboxamide, 1-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-4-formyl-N-(phenylmethoxy)- (CA INDEX NAME)



RN 210916-47-5 CAPLUS


CN 2-Piperidinecarboxamide, N-(phenylmethoxy)-1-[[4-(4,5,6,7-tetrafluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 210916-48-6 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-3-[[(phenylmethoxy)amino]carbonyl]-, methyl ester (CA INDEX NAME)



RN 210916-49-7 CAPLUS


CN 2-Piperazinecarboxamide, 1-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N-(phenylmethoxy)-4-[(tetrahydro-2H-pyran-4-yl)carbonyl]- (CA INDEX NAME)



RN 210916-50-0 CAPLUS

CN 1,3-Piperazinedicarboxamide, N1-(1,1-dimethylethyl)-N3-(phenylmethoxy)-4-[[4-(4,5,6,7-tetrafluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210916-52-2 CAPLUS

CN 2-Piperidinecarboxamide, N-hydroxy-N-(4-morpholinylmethyl)-1-[[4-(4,5,6,7-tetrafluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210916-53-3 CAPLUS

CN 2-Piperidinecarboxamide, 1-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N-hydroxy-N-methyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210916-54-4 CAPLUS

CN 1,3-Piperazinedicarboxamide, 4-[[4-(5-cyano-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N1,N1-dimethyl-N3-(phenylmethoxy)-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210916-55-5 CAPLUS


CN 2-Piperidinecarboxamide, 1-[[4-(5-cyano-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N-methoxy-N-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 210916-60-2 CAPLUS

CN 2-Piperidinecarboxamide, 1-[[4-(5-chloro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]sulfonyl]-N-hydroxy- (CA INDEX NAME)



RN 210916-61-3 CAPLUS


CN 2-Piperidinecarboxamide, 1-[[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]sulfonyl]-N-hydroxy- (CA INDEX NAME)



RN 210916-97-5 CAPLUS


CN 2-Piperidinecarboxylic acid, 1-[[4-(6-chloro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 210917-01-4 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[[4-(5-chloro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]- (CA INDEX NAME)



RN 210917-04-7 CAPLUS


CN 2-Piperidinecarboxylic acid, 1-[[4-(5-methyl-1H-indol-3-yl)-1-piperidinyl]sulfonyl]- (CA INDEX NAME)



RN 416846-37-2 CAPLUS

CN 2-Piperazinecarboxamide, 1-[[4-(5-cyano-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-4-[(dimethylamino)sulfonyl]-N-hydroxy-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 416846-38-3 CAPLUS

CN 2-Piperazinecarboxamide, 4-(cyclopropylmethyl)-1-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 210917-46-7P 210917-47-8P 210917-51-4P

210917-52-5P 210917-53-6P 210917-55-8P

210917-56-9P 210917-57-0P 210917-58-1P

210917-59-2P 210917-68-3P 210917-69-4P


416846-40-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of sulfamides as metalloprotease inhibitors)


RN 210917-46-7 CAPLUS

CN 1,3-Piperazinedicarboxylic acid, 4-[[4-[5-fluoro-1-[[2-(trimethylsilyl)ethyl]sulfonyl]-1H-indol-3-yl]-1-piperidinyl]sulfonyl]-, 1-(phenylmethyl) ester (CA INDEX NAME)



RN 210917-47-8 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[[4-[5-fluoro-1-[[2-(trimethylsilyl)ethyl]sulfonyl]-1H-indol-3-yl]-1-piperidinyl]sulfonyl]-3-[(hydroxyamino)carbonyl]-, phenylmethyl ester (CA INDEX NAME)



RN 210917-51-4 CAPLUS

CN 1,3-Piperazinedicarboxylic acid, 4-[[4-(4,5,6,7-tetrafluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-, 1-(1,1-dimethylethyl) ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210917-52-5 CAPLUS

CN 1-Piperazinecarboxylic acid, 3-[[(phenylmethoxy) amino] carbonyl]-4-[[4-(4,5,6,7-tetrafluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-, 1,1-dimethylethyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210917-53-6 CAPLUS

CN 2-Piperazinecarboxamide, N-(phenylmethoxy)-1-[[4-(4,5,6,7-tetrafluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210917-55-8 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-, methyl ester, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210917-56-9 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210917-57-0 CAPLUS

CN 2-Piperidinecarboxamide, 1-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N-(phenylmethoxy)-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210917-58-1 CAPLUS


CN 2-Piperidinecarboxamide, 1-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N-methyl-N-(phenylmethoxy)-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 210917-59-2 CAPLUS


CN 2-Piperidinecarboxylic acid, 1-[[4-(5-hydroxy-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N-methyl-N-(phenylmethoxy)-, (2R)- (CA INDEX NAME)



RN 210917-68-3 CAPLUS

CN 2-Piperazinecarboxamide, 1-[[4-[5-cyano-1-[[2-(trimethylsilyl)ethyl]sulfonyl]-1H-indol-3-yl]-1-piperidinyl]sulfonyl]-N-(phenylmethoxy)-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210917-69-4 CAPLUS

CN 2-Piperazinecarboxamide, 1-[[4-[5-cyano-1-[[2-(trimethylsilyl)ethyl]sulfonyl]-1H-indol-3-yl]-1-piperidinyl]sulfonyl]-4-[(dimethylamino)sulfonyl]-N-(phenylmethoxy)-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 416846-40-7 CAPLUS

CN 2-Piperazinecarboxamide, 1-[[4-[5-fluoro-1-[[2-(trimethylsilyl)ethyl]sulfonyl]-1H-indol-3-yl]-1-piperidinyl]sulfonyl]-N-(phenylmethoxy)-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1998:498326 CAPLUS Full-text

DOCUMENT NUMBER: 129:148991

ORIGINAL REFERENCE NO.: 129:30373a,30376a

TITLE: Preparation of N-sulfamoylpiperidine-2-hydroxamic
acids and analogs as metalloproteinase inhibitors

INVENTOR(S): Broka, Chris Allen; Campbell, Jeffrey Allen;
Castelhamo, Arlindo Lucas; Chen, Jian Jeffrey;
Hendricks, Robert Than; Melnick, Michael Joseph;
Walker, Keith Adrian Murray

PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.; Agouron
Pharmaceuticals, Inc.

SOURCE: Ger. Offen., 84 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent


LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19802350	A1	19980730	DE 1998-19802350	19980122
CA 2278694	A1	19980730	CA 1998-2278694	19980114
CA 2278694	C	20060926		
WO 9832748	A1	19980730	WO 1998-EP180	19980114
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9866140	A	19980818	AU 1998-66140	19980114
AU 730127	B2	20010222		
EP 958287	A1	19991124	EP 1998-907943	19980114
EP 958287	B1	20020911		
EP 958287	B2	20080409		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK				
BR 9807508	A	20000321	BR 1998-7508	19980114
NZ 336625	A	20010427	NZ 1998-336625	19980114
HU 2000000941	A2	20010428	HU 2000-941	19980114
HU 2000000941	A3	20020628		
JP 2001523222	T	20011120	JP 1998-531537	19980114
JP 3563411	B2	20040908		
AT 223909	T	20020915	AT 1998-907943	19980114
CN 1093125	C	20021023	CN 1998-803233	19980114
ES 2183331	T3	20030316	ES 1998-907943	19980114
ZA 9800376	A	19980723	ZA 1998-376	19980116
IN 1998MA00105	A	20050304	IN 1998-MA105	19980116
IT 1298163	B1	19991220	IT 1998-MI91	19980120
FR 2758559	A1	19980724	FR 1998-601	19980121
GB 2321641	A	19980805	GB 1998-1393	19980122
GB 2321641	B	20010401		
ES 2136037	A1	19991101	ES 1998-113	19980122

ES 2136037	B1	20001116		
NO 9903587	A	19990922	NO 1999-3587	19990722
NO 313635	B1	20021104		
MX 9906822	A	20000131	MX 1999-6822	19990722
PRIORITY APPLN. INFO.:			US 1997-36714P	P 19970123
			US 1997-62209P	P 19971016
			WO 1998-EP180	W 19980114
OTHER SOURCE(S):	MARPAT 129:148991			
GI				



II


AB R10COCR1R2NR3SO2NR20R21 [I; R1-R3 = H, (CO-interrupted) alkyl, heterocyclyl(alkyl), (hetero)aryl(alkyl), etc.; R1R2, R1R3, R2R3 = atoms to complete a ring; R10 = NR11OR12; R11,R12 = H or (ar)alkyl; R20,R21 = H, alkyl, (hetero)aryl[alk(en)yl], etc.; NR20R21heterocyclyl] were prepared Thus, (R)-1-[4-(4-chlorobenzoyl)piperidine-1-sulfonyl]piperidine-2- carboxylic acid was amidated by H2NOCMe3 and the product deprotected to give title compound (R)-II. Data for biol. activity of I were given.

IT 210915-38-1P 210915-40-5P 210915-57-4P
210915-59-6P 210915-60-9P 210915-61-0P
210915-69-8P 210915-71-2P 210915-72-3P
210915-76-7P 210915-78-9P 210915-83-6P
210915-86-9P 210915-87-0P 210915-88-1P
210915-89-2P 210915-90-5P 210915-91-6P
210915-92-7P 210915-93-8P 210915-94-9P
210915-95-0P 210915-96-1P 210916-01-1P
210916-05-5P 210916-08-8P 210916-09-9P
210916-14-6P 210916-16-8P 210916-17-9P
210916-46-4P 210916-47-5P 210916-48-6P
210916-49-7P 210916-50-0P 210916-51-1P
210916-52-2P 210916-53-3P 210916-54-4P
210916-55-5P 210916-60-2P 210916-61-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-sulfamoylpiperidine-2-hydroxamic acids and analogs as metalloproteinase inhibitors)


RN 210915-38-1 CAPLUS

CN 2-Piperidinecarboxamide, 1-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N-hydroxy- (CA INDEX NAME)




RN 210915-40-5 CAPLUS

CN 2-Piperidinecarboxamide, 1-[[4-(6-chloro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N-hydroxy- (CA INDEX NAME)




RN 210915-57-4 CAPLUS

CN 2-Piperidinecarboxamide, 1-[[4-(5-chloro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N-hydroxy- (CA INDEX NAME)




RN 210915-59-6 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-3-[(hydroxyamino)carbonyl]-, phenylmethyl ester (CA INDEX NAME)




RN 210915-60-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[4-(6-chloro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-3-[(hydroxyamino)carbonyl]-, phenylmethyl ester (CA INDEX NAME)




RN 210915-61-0 CAPLUS

CN 2-Piperazinecarboxamide, 4-acetyl-N-hydroxy-1-[[4-(6-methyl-1H-indol-3-yl)-1-piperidinyl]sulfonyl]- (CA INDEX NAME)



RN 210915-69-8 CAPLUS


CN 2-Piperidinecarboxamide, 1-[[4-(4-chloro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N-hydroxy- (CA INDEX NAME)



RN 210915-71-2 CAPLUS


CN 2-Piperidinecarboxamide, 1-[[4-(6-fluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 210915-72-3 CAPLUS

CN 2-Piperidinecarboxamide, N-hydroxy-1-[[4-(5-methoxy-1H-indol-3-yl)-1-piperidinyl]sulfonyl]- (CA INDEX NAME)



RN 210915-76-7 CAPLUS


CN 2-Piperidinecarboxamide, N-hydroxy-1-[[4-(5-hydroxy-1H-indol-3-yl)-1-piperidinyl]sulfonyl]- (CA INDEX NAME)



RN 210915-78-9 CAPLUS

CN 2-Piperidinecarboxamide, 1-[[4-(5-cyano-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N-hydroxy-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210915-83-6 CAPLUS


CN 2-Piperidinecarboxamide, N-hydroxy-1-[[4-(4,5,6,7-tetrafluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 210915-86-9 CAPLUS

CN 1,3-Piperazinedicarboxamide, N1-(1,1-dimethylethyl)-4-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N3-hydroxy- (CA INDEX NAME)




RN 210915-87-0 CAPLUS

CN 1-Piperazinecarboxylic acid, 3-[(hydroxyamino)carbonyl]-4-[[4-[4,5,6,7-tetrafluoro-1-[[2-(trimethylsilyl)ethyl]sulfonyl]-1H-indol-3-yl]-1-piperidinyl]sulfonyl]-, phenylmethyl ester (CA INDEX NAME)




RN 210915-88-1 CAPLUS

CN 1-Piperazinecarboxylic acid, 3-[(hydroxyamino)carbonyl]-4-[[4-(4,5,6,7-tetrafluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-, phenylmethyl ester (CA INDEX NAME)




RN 210915-89-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-3-[(hydroxyamino)carbonyl]-, methyl ester (CA INDEX NAME)



RN 210915-90-5 CAPLUS


CN 2-Piperazinecarboxamide, 1-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N-hydroxy-4-[(tetrahydro-2H-pyran-4-yl)carbonyl]- (CA INDEX NAME)



RN 210915-91-6 CAPLUS

CN 2-Piperidinecarboxamide, 1-[[4-[5-(acetylamino)-1H-indol-3-yl]-1-piperidinyl]sulfonyl]-N-hydroxy-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210915-92-7 CAPLUS

CN 2-Piperazinecarboxamide, 4-[(2S)-2-amino-3-methyl-1-oxobutyl]-1-[[4-(6-fluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N-hydroxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 210915-93-8 CAPLUS

CN 1,3-Piperazinedicarboxamide, N3-hydroxy-N1,N1-dimethyl-4-[[4-(4,5,6,7-tetrafluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210915-94-9 CAPLUS


CN 2-Piperazinecarboxamide, 4-(cyclopropylmethyl)-1-[[4-(6-fluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 210915-95-0 CAPLUS

CN 2-Piperazinecarboxamide, 4-[(dimethylamino)sulfonyl]-1-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N-hydroxy- (CA INDEX NAME)



RN 210915-96-1 CAPLUS


CN 2-Piperazinecarboxamide, 4-[bis(dimethylamino)phosphinyl]-1-[[4-(6-fluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N-hydroxy- (CA INDEX NAME)



RN 210916-01-1 CAPLUS

CN 1,3-Piperazinedicarboxamide, 4-[[4-(5-cyano-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N1-(1,1-dimethylethyl)-N3-hydroxy-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210916-05-5 CAPLUS

CN 2-Piperazinecarboxamide, 1-[[4-(5-cyano-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N-hydroxy-4-(4-morpholinylcarbonyl)-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210916-08-8 CAPLUS

CN 2-Piperidinecarboxamide, 1-[[4-[5-cyano-1-(methylsulfonyl)-1H-indol-3-yl]-1-piperidinyl]sulfonyl]-N-hydroxy-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210916-09-9 CAPLUS

CN 3-Thiomorpholinecarboxamide, 4-[[4-(5-cyano-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N-hydroxy-2,2-dimethyl-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210916-14-6 CAPLUS


CN 2-Piperazinecarboxamide, 1-[[4-(5-cyano-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N-hydroxy-4-(2-pyrazinylcarbonyl)-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 210916-16-8 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[4-[6-chloro-1-[[2-(trimethylsilyl)ethyl]sulfonyl]-1H-indol-3-yl]-1-piperidinyl]sulfonyl]-3-[(hydroxyamino)carbonyl]-, phenylmethyl ester (CA INDEX NAME)




RN 210916-17-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[4-[6-fluoro-1-[[2-(trimethylsilyl)ethyl]sulfonyl]-1H-indol-3-yl]-1-piperidinyl]sulfonyl]-3-[(hydroxyamino)carbonyl]-, phenylmethyl ester (CA INDEX NAME)



RN 210916-46-4 CAPLUS


CN 2-Piperazinecarboxamide, 1-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-4-formyl-N-(phenylmethoxy)- (CA INDEX NAME)




RN 210916-47-5 CAPLUS

CN 2-Piperidinecarboxamide, N-(phenylmethoxy)-1-[[4-(4,5,6,7-tetrafluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210916-48-6 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-3-[[(phenylmethoxy) amino]carbonyl]-, methyl ester
 (CA INDEX NAME)




RN 210916-49-7 CAPLUS
 CN 2-Piperazinecarboxamide, 1-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N-(phenylmethoxy)-4-[(tetrahydro-2H-pyran-4-yl)carbonyl]- (CA INDEX NAME)



RN 210916-50-0 CAPLUS
 CN 1,3-Piperazinedicarboxamide, N1-(1,1-dimethylethyl)-N3-(phenylmethoxy)-4-[[4-(4,5,6,7-tetrafluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-, (3R)-
 (CA INDEX NAME)


Absolute stereochemistry.



RN 210916-51-1 CAPLUS

CN 1,3-Piperazinedicarboxamide, N1,N1-dimethyl-N3-(phenylmethoxy)-4-[[4-(4,5,6,7-tetrafluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210916-52-2 CAPLUS

CN 2-Piperidinecarboxamide, N-hydroxy-N-(4-morpholinylmethyl)-1-[[4-(4,5,6,7-tetrafluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210916-53-3 CAPLUS

CN 2-Piperidinecarboxamide, 1-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N-hydroxy-N-methyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210916-54-4 CAPLUS

CN 1,3-Piperazinedicarboxamide, 4-[[4-(5-cyano-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N1,N1-dimethyl-N3-(phenylmethoxy)-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.




RN 210916-55-5 CAPLUS

CN 2-Piperidinecarboxamide, 1-[[4-(5-cyano-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N-methoxy-N-methyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210916-60-2 CAPLUS
 CN 2-Piperidinecarboxamide, 1-[[4-(5-chloro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]sulfonyl]-N-hydroxy- (CA INDEX NAME)




RN 210916-61-3 CAPLUS
 CN 2-Piperidinecarboxamide, 1-[[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]sulfonyl]-N-hydroxy- (CA INDEX NAME)



IT 210916-97-5P 210917-01-4P 210917-04-7P
 210917-46-7P 210917-47-8P 210917-51-4P
 210917-52-5P 210917-53-6P 210917-55-8P
 210917-56-9P 210917-57-0P 210917-58-1P
 210917-59-2P 210917-67-2P 210917-68-3P
 210917-69-4P 210917-70-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of N-sulfamoylpiperidine-2-hydroxamic acids and analogs as
 metalloproteinase inhibitors)


RN 210916-97-5 CAPLUS
 CN 2-Piperidinecarboxylic acid, 1-[[4-(6-chloro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 210917-01-4 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[[4-(5-chloro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]- (CA INDEX NAME)




RN 210917-04-7 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[[4-(5-methyl-1H-indol-3-yl)-1-piperidinyl]sulfonyl]- (CA INDEX NAME)




RN 210917-46-7 CAPLUS

CN 1,3-Piperazinedicarboxylic acid, 4-[[4-[5-fluoro-1-[[2-(trimethylsilyl)ethyl]sulfonyl]-1H-indol-3-yl]-1-piperidinyl]sulfonyl]-, 1-(phenylmethyl) ester (CA INDEX NAME)



RN 210917-47-8 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[[4-[5-fluoro-1-[[2-(trimethylsilyl)ethyl]sulfonyl]-1H-indol-3-yl]-1-piperidinyl]sulfonyl]-3-[(hydroxyamino)carbonyl]-, phenylmethyl ester (CA INDEX NAME)



RN 210917-51-4 CAPLUS

CN 1,3-Piperazinedicarboxylic acid, 4-[[4-(4,5,6,7-tetrafluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-, 1-(1,1-dimethylethyl) ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210917-52-5 CAPLUS

CN 1-Piperazinecarboxylic acid, 3-[[(phenylmethoxy) amino] carbonyl]-4-[[4-(4,5,6,7-tetrafluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-, 1,1-dimethylethyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210917-53-6 CAPLUS

CN 2-Piperazinecarboxamide, N-(phenylmethoxy)-1-[[4-(4,5,6,7-tetrafluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210917-55-8 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-, methyl ester, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210917-56-9 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210917-57-0 CAPLUS

CN 2-Piperidinecarboxamide, 1-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N-(phenylmethoxy)-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210917-58-1 CAPLUS


CN 2-Piperidinecarboxamide, 1-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N-methyl-N-(phenylmethoxy)-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 210917-59-2 CAPLUS


CN 2-Piperidinecarboxylic acid, 1-[[4-(5-hydroxy-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N-methyl-N-(phenylmethoxy)-, (2R)- (CA INDEX NAME)



RN 210917-67-2 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[[4-[5-cyano-1-(methylsulfonyl)-1H-indol-3-yl]-1-piperidinyl]sulfonyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210917-68-3 CAPLUS

CN 2-Piperazinecarboxamide, 1-[[4-[5-cyano-1-[[2-(trimethylsilyl)ethyl]sulfonyl]-1H-indol-3-yl]-1-piperidinyl]sulfonyl]-N-(phenylmethoxy)-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210917-69-4 CAPLUS

CN 2-Piperazinecarboxamide, 1-[[4-[5-cyano-1-[[2-(trimethylsilyl)ethyl]sulfonyl]-1H-indol-3-yl]-1-piperidinyl]sulfonyl]-4-[(dimethylamino)sulfonyl]-N-(phenylmethoxy)-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210917-70-7 CAPLUS

CN 2-Piperazinecarboxamide, 1-[[4-(5-cyano-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-4-[(dimethylamino)sulfonyl]-N-(phenylmethoxy)-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



=> log off

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

STN INTERNATIONAL LOGOFF AT 14:35:01 ON 30 MAR 2009